Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17

作者：

Mann, Johannes F. E. ^{[1
,2
]}

Muskiet, Marcel H. A. ^{[3
]}

机构：

[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany

[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany

[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands

来源：

KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期

关键词：

RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;

D O I：

10.1016/j.kint.2020.08.036

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：314 / 318

页数：5

共 50 条

[1] Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists (vol 99, pg 314, 2021)
Mann, J. F. E.
Muskiet, M. H. A.
KIDNEY INTERNATIONAL, 2021, 100 (06) : 1351 - 1352
[2] Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
Scheen, Andre J.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 127 : 224 - 237
[3] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
Farngren, Johan
Ahren, Bo
METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
[4] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
Ahrén, B
Schmitz, O
HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
[5] Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
Brown, Dominique Xavier
Evans, Marc
JOURNAL OF NUTRITION AND METABOLISM, 2012, 2012
[6] Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure
Zheng, S. L.
Collins, P.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 202 - 203
[7] The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
Dara L. Eckerle Mize
Marzieh Salehi
Current Diabetes Reports, 2013, 13 : 307 - 318
[8] Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Sachinidis, Alexandros
Nikolic, Dragana
Stoian, Anca Pantea
Papanas, Nikolaos
Tarar, Omer
Rizvi, Ali A.
Rizzo, Manfredi
METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
[9] Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Stonehouse, Anthony
Okerson, Ted
Kendall, David
Maggs, David
CURRENT DIABETES REVIEWS, 2008, 4 (02) : 101 - 109
[10] Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
Davies, Melanie J.
Bianchi, Cristina
Del Prato, Stefano
METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 107

← 1 2 3 4 5 →